FDA limits research of former AHA president for submitting false information

BMJ 2002; 325 doi: (Published 14 December 2002) Cite this as: BMJ 2002;325:1377
  1. Janice Hopkins Tanne
  1. New York

    Just days before he completed his year as president of the American Heart Association on 30 June, Dr David Faxon signed a consent agreement with the Food and Drug Administration limiting his clinical research.

    On 19 June 2002 Dr Faxon agreed that for three years he would not be the principal investigator for more than two FDA regulated clinical investigations at any one time, and that he would not be the principal clinical investigator for a study that enrolled more than 25 subjects. …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial